Skip to main content
. 2020 Jan 13;2020(1):CD012643. doi: 10.1002/14651858.CD012643.pub3

Knight‐Greenfield 2013.

Notes Title: Interim FDG PET‐CT to predict progression‐free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).
(Conference abstract)
Aim

  • To determine the best predictor of PFS among various variables of tumour metabolic measurements at baseline and at interim PET‐CT compared to conventional methods in individuals with classic HL


Study design

  • Retrospective


Country/treatment centre(s)

  • Not reported


Number of included participants

  • 58


Inclusion criteria

  • Diagnosed classic HL, ABVD therapy, minimal follow‐up of 2 years


Exclusion criteria

  • Not reported


Treatment

  • ABVD


Primary outcome measure(s)

  • Progression‐free survival